Target Price .09 to 2.1, page-22

As I understand it, Prof Parker is trialling the BPO Heart Rate Technology in melancholic and non-melancholic depression as we speak.

Trial results are expected within six months.

If Parker validates the tech, BPO will be mightily encouraged.

Having researched the tech for 10 years, HRT inventor Dr Hans Stampfer seems optimistic.

He says "the anticipated success of the independent trial...will go a long way in confirming our depression test as a reliable and robust quantitative test for a debilitating condition that affects millions of people worldwide.”

Meanwhile, I note two buyers have posted orders for a total of 12m shares @ 3c.

If sales follow we may see a material pickup in volume ahead of the AGM.